NOCIL (NOCIL)

FairStock Score: 23/100 — RISKY

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Near-zero debt with Debt/Equity of 0.01 provides balance sheet safety.
• Modest dividend yield of 1.38% offers some income while waiting.
• Promoter holding of 33.76% provides reasonable owner alignment.
• Book value of ₹104.92 offers a downside reference, though price is well above it.
• Quarterly sales of ₹316 Cr show the business is still generating meaningful scale.

Concerns

• ROE of 3.78% and ROCE of 6.65% indicate poor returns on shareholder capital.
• P/E of 38.40 is very expensive given flat-to-negative sales and profit growth.
• Piotroski F-Score of 3/9 signals weak financial health and deteriorating fundamentals.
• Latest quarter net margin is only about 2.8% (₹9 Cr profit on ₹316 Cr sales), leaving little cushion.

AI Analysis

When I look at NOCIL, I first check for a durable business with earning power. The numbers do not excite me. This specialty chemicals company has a clean balance sheet—debt/equity of 0.01—but a clean balance sheet is not a business. Its return on equity is just 3.78% and ROCE is 6.65%. A business earning this return on capital must be exceptional to justify a premium price. This is not. Sales growth is -0.72% and profit growth is -1.63%. The latest quarter shows sales of ₹316 Cr and net profit of only ₹9 Cr, a net margin of under 3%. That is thin and vulnerable. At ₹182.60, the market cap is ₹2,414 Cr. With book value of ₹104.92, the stock trades at 1.74 times book, and the P/E is 38.40. For a company with declining sales and profits, I usually demand a price that provides a margin of safety. Here I see the opposite. The Piotroski F-score of 3/9 reinforces my concern: the underlying financials are weak, not improving. Promoter holding is 33.76%, which gives some alignment, but minority investors still need a business that earns a return. I find no compelling moat in these figures. The dividend yield of 1.38% is a small comfort but does not compensate for a 38 times earnings entry into a zero-growth situation. Value investing requires patience, not patience with overpayments. I would rather wait until NOCIL improves its returns, shows consistent quarterly earnings, and offers a price—perhaps well below book—before considering it. This is not a wonderful company at a fair price; it is a mediocre-return business at a demanding valuation. For the Indian retail investor, my advice: leave this in the 'too hard' pile unless operations and returns show a clear, long-term improvement.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer